It remain has many factors influence the experimentation to cause the false positive results. Moreover, 85 patients were certainly few and follow-up time was short to be able to conclude firmly on any of the findings in our study, particularly using multivariate analysis. However, because of patients with negative expression of these genes indeed receive more benefit from platinum based chemotherapy in our study, the

Selleck Bindarit combined detection of the mRNA expression of these genes might better individualize the efficacy of chemotherapy and improve survival in this common and vital cancer. Funding This research was supported by Guangxi Scientific research and technology development projects (Grant No. 10124001A-44) Acknowledgements This research was supported by Guangxi Scientific selleck research and technology development projects (Grant No. 10124001A-44). Thanks for data sorting and processing by Guang-Yao Ma and Man-Hong Li. References 1. Chen W, Zhang S, Zou X: Evaluation on the incidence, mortality and tendency of lung cancer in China. Thoracic Cancer 2010, 1:35–40.CrossRef 2. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, et al.: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983–991.PubMedCrossRef EX 527 price 3. Takayama S, Sato T, Krajewski S, Kochel K,

Irie S, Milian JA, Reed JC: Cloning and functional analysis of BAG-1: A novel Bcl-2-binding protein with anti-cell death activity. Cell 1995, 80:279–284.PubMedCrossRef 4. Krajewska M, Turner BC, Shabaik A, Krajewski S, Reed JC: Expression of BAG-1 protein correlates with aggressive behavior

of prostate cancers. Prostate 2006, 66:801–810.PubMedCrossRef 5. Liu H, Liang Y, Li Y, Wang J, Wu H, Wang Y, Tang SC, Chen J, Zhou Q: Gene silencing of BAG-1 modulates apoptotic genes and sensitizes lung cancer cell lines to cisplatin-induced apoptosis. Cancer Biol Ther 2010, 9:832–840.PubMedCrossRef 6. Kennedy RD, Quinn JE, Johnston PG, Harkin DP: BRCA1: mechanisms of inactivation and implications for management of http://www.selleck.co.jp/products/CHIR-99021.html patients. Lancet 2002, 360:1007–1014.PubMedCrossRef 7. Bepler G, Gautam A, McIntyre LM, Beck AF, Chervinsky DS, Kim YC, Pitterle DM, Hyland A: Prognostic significance of molecular genetic aberrations on chromosome segment 11p15.5 in non-small-cell lung cancer. J Clin Oncol 2002, 20:1353–1360.PubMedCrossRef 8. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006, 24:4731–4737.PubMedCrossRef 9. Dumontet C, Isaac S, Souquet PJ, Bejui-Thivolet F, Pacheco Y, Peloux N, Frankfurter A, Luduena R, Perol M: Expression of class III beta tubulin in non-small cell lung cancer is correlated with resistance to taxane chemotherapy.